CAR-NK cell therapy combined with checkpoint inhibition induces a NKT cell response in glioblastoma

被引：0

作者：

Strassheimer, Florian ^{[1
,2
,3
,4
]}

Elleringmann, Philipp ^{[1
,2
,3
,4
]}

Roller, Bastian ^{[1
,2
,3
,4
]}

Macas, Jadranka ^{[2
,5
]}

Alekseeva, Tijna ^{[2
,6
]}

Aliraj, Blerina ^{[2
,7
]}

Weber, Katharina ^{[2
,3
,4
,5
]}

Demes, Melanie ^{[8
]}

Tonn, Torsten ^{[9
]}

Reib, Yvonne ^{[2
,3
,4
,5
]}

Plate, Karl ^{[2
,3
,4
,5
]}

Weigert, Andreas ^{[2
,3
,4
,7
]}

Wels, Winfried ^{[2
,3
,4
,6
]}

Steinbach, Joachim ^{[1
,2
,3
,4
]}

Burger, Michael ^{[1
,2
,3
,4
]}

机构：

[1] Goethe Univ Frankfurt, Univ Hosp, Dr Senckenberg Inst Neurooncol, Frankfurt, Germany

[2] Goethe Univ Frankfurt, Frankfurt Canc Inst FCI, Frankfurt, Germany

[3] German Canc Consortium DKTK, Heidelberg, Germany

[4] German Canc Res Ctr, Heidelberg, Germany

[5] Goethe Univ Frankfurt, Univ Hosp, Inst Neurol, Edinger Inst, Frankfurt, Germany

[6] Georg Speyer Haus, Inst Tumor Biol & Expt Therapy, Frankfurt, Germany

[7] Goethe Univ Frankfurt, Inst Biochem 1, Frankfurt, Germany

[8] Goethe Univ Frankfurt, Univ Hosp, Dr Senckenberg Inst Pathol, Frankfurt, Germany

[9] Goethe Univ Frankfurt, Inst Transfus Med & Immune Hematol, German Red Cross Blood Donat Serv Baden Wurttembe, Frankfurt, Germany

来源：

EUROPEAN JOURNAL OF IMMUNOLOGY | 2024年 / 54卷

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

1921 - WS4

引用

页码：302 / 302

页数：1

共 50 条

[31] CAR-NK cell therapy: latest updates from the 2024 ASH annual meeting
Kong, Ran
Liu, Bingyu
Wang, Hua
Lu, Tiange
Zhou, Xiangxiang
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2025, 18 (01)
[32] CAR-NK cell therapy for hematological malignancies: recent updates from ASH 2022
Ruihao Huang
Qin Wen
Xi Zhang
Journal of Hematology & Oncology, 16
[33] CAR-NK cell therapeutics for hematologic malignancies: hope is on the horizon
Xu, Kai-lin
Cheng, Hai
BLOOD SCIENCE, 2019, 1 (02): : 156 - 160
[34] HSC and iPS cell-derived CAR-NK cells as reliable cell-based therapy solutions
Arias, Jonathan
Yu, Jingwei
Varshney, Mukesh
Inzunza, Jose
Nalvarte, Ivan
STEM CELLS TRANSLATIONAL MEDICINE, 2021, 10 (07) : 987 - 995
[35] Optimisation of a primary human CAR-NK cell manufacturing pipeline
Pfefferle, Aline
Contet, Julian
Wong, Kahlia
Chen, Charlotte
Verhoeyen, Els
Slichter, Chloe K.
Schluns, Kimberly S.
Cursons, Joseph
Berry, Richard
Nikolic, Iva
Rautela, Jai
Huntington, Nicholas D.
CLINICAL & TRANSLATIONAL IMMUNOLOGY, 2024, 13 (05)
[36] Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy
Ying Gong
Roel G. J. Klein Wolterink
Jianxiang Wang
Gerard M. J. Bos
Wilfred T. V. Germeraad
Journal of Hematology & Oncology, 14
[37] Unlocking the Potential of CAR-NK Cell Therapy: Overcoming Barriers and Challenges in the Treatment of Myeloid Malignancies
Zhang, Anqi
Yang, Xingcheng
Zhang, Yicheng
Yu, Xiaoxuan
Mu, Wei
Wei, Jia
MOLECULAR CANCER THERAPEUTICS, 2025, 24 (04) : 536 - 549
[38] Synergistic treatment strategy: combining CAR-NK cell therapy and radiotherapy to combat solid tumors
He, Jie
Yan, Yushan
Zhang, Jun
Wei, Zhiming
Li, Huashun
Xing, Ligang
FRONTIERS IN IMMUNOLOGY, 2023, 14
[39] Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy
Gong, Ying
Klein Wolterink, Roel G. J.
Wang, Jianxiang
Bos, Gerard M. J.
Germeraad, Wilfred T. V.
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2021, 14 (01)
[40] Current Perspectives on "Off-The-Shelf" Allogeneic NK and CAR-NK Cell Therapies
Heipertz, Erica L.
Zynda, Evan R.
Stav-Noraas, Tor Espen
Hungler, Andrew D.
Boucher, Shayne E.
Kaur, Navjot
Vemuri, Mohan C.
FRONTIERS IN IMMUNOLOGY, 2021, 12

← 1 2 3 4 5 →